2-[(3R,6R)-1-(6-methoxy-2-pyrimidin-2-ylpyridine-3-carbonyl)-6-methylpiperidin-3-yl]oxypyridine-4-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-[(3R,6R)-1-(6-methoxy-2-pyrimidin-2-ylpyridine-3-carbonyl)-6-methylpiperidin-3-yl]oxypyridine-4-carboxylic acid
• 化学式: C₂₃H₂₃N₅O₅
• 分子量: 449.5
• InChiKey: PJSBIXYFIBRAMA-GDBMZVCRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  128
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• [EN] 2-PYRIDYLOXY-4-ESTER OREXIN RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS DE TYPE 2-PYRYDYLOXY-4-ESTER ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2014099696A1

  公开（公告）日：2014-06-26

  The present invention is directed to 2-pyridyloxy-4-ester compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ester compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及2-吡啶氧基-4-酯类化合物，其为俄雷欣受体拮抗剂。本发明还涉及在俄雷欣受体参与的神经和精神障碍和疾病的潜在治疗或预防中使用本文所述的2-吡啶氧基-4-酯类化合物。本发明还涉及包含这些化合物的药物组合物。本发明还涉及在俄雷欣受体参与的这些疾病的预防或治疗中使用这些药物组合物。
• 2-PYRIDYLOXY-4-ESTER OREXIN RECEPTOR ANTAGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2934527A1

  公开（公告）日：2015-10-28
• USE OF OX1R ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES
  申请人：INSERM (Institut National de la Santé et de la Recherche Médicale)

  公开号：EP3223803A1

  公开（公告）日：2017-10-04
• METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER
  申请人：INSERM (Institut National de la Santé et de la Recherche Médicale)

  公开号：EP3218007A1

  公开（公告）日：2017-09-20
• METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY DISEASES
  申请人：INSERM (Institut National de la Santé et de la Recherche Médicale)

  公开号：EP3454857A1

  公开（公告）日：2019-03-20